Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Genovie AB currently maintains 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 4 distinct art units. This correspondence between actions, examiners, and art units indicates a decentralized prosecution environment where every active case is being evaluated by a different individual in a different specialized unit.
The busiest examiner for this portfolio is WESTON, ALYSSA G, who is currently handling 1 pending office action. Despite being the busiest, this examiner only manages a fraction of the total 4 pending office actions. This distribution means that the practitioner must manage relationships and respond to the unique requirements of distinct examiners simultaneously, which increases the complexity of the prosecution strategy compared to a more centralized portfolio.
With several pending office actions spread across 4 distinct art units, the portfolio faces a wide range of examination perspectives within the biotechnology sector. Success in this environment requires a versatile approach that can address the specific technical and legal hurdles presented by each examiner. Practitioners should prioritize individual case strategies, as the 1 pending action under WESTON, ALYSSA G is just one of the independent paths currently being pursued.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTON, ALYSSA G | 1 | 59.8% | +50.9% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.6% |
| MEYERING, SHABANA SHABBEER | 1 | 70.6% | +42.3% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18320900 | AN ENGINEERED TWO-PART CELLULAR DEVICE FOR DISCOVERY AND CHARACTERISATION OF T-CELL RECEPTOR INTERACTION WITH COGNATE ANTIGEN | WESTON, ALYSSA G | 60d overdue |
| 16632301 | A TWO-COMPONENT VECTOR LIBRARY SYSTEM FOR RAPID ASSEMBLY AND DIVERSIFICATION OF FULL-LENGTH T-CELL RECEPTOR OPEN READING FRAMES | MEYERING, SHABANA SHABBEER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18320900 | AN ENGINEERED TWO-PART CELLULAR DEVICE FOR DISCOVERY AND CHARACTERISATION OF T-CELL RECEPTOR INTERACTION WITH COGNATE ANTIGEN | WESTON, ALYSSA G | 60d overdue |
| 16347691 | AN ENGINEERED MULTI-COMPONENT SYSTEM FOR IDENTIFICATION AND CHARACTERISATION OF T-CELL RECEPTORS, T-CELL ANTIGENS AND THEIR FUNCTIONAL INTERACTION | WILSON, MICHAEL C | 57d |
| 17907532 | METHODS TO GENERATE VACCINE COMPOSITIONS THAT PRIME HUMAN LEUKOCYTE ANTIGEN CLASS I RESTRICTED CD8 T-CELL RESPONSES AGAINST VIRAL NON-VIRION-INTEGRAL DERIVED EPITOPES | CHEN, STACY BROWN | — |
| 16632301 | A TWO-COMPONENT VECTOR LIBRARY SYSTEM FOR RAPID ASSEMBLY AND DIVERSIFICATION OF FULL-LENGTH T-CELL RECEPTOR OPEN READING FRAMES | MEYERING, SHABANA SHABBEER | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1672 | 1 |
| 1635 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18320900 | AN ENGINEERED TWO-PART CELLULAR DEVICE FOR DISCOVERY AND CHARACTERISATION OF T-CELL RECEPTOR INTERACTION WITH COGNATE ANTIGEN | WESTON, ALYSSA G | 1633 | §102§103 | Final Rejection | 60d overdue | Pending | May 19, 2023 |
| 17907532 | METHODS TO GENERATE VACCINE COMPOSITIONS THAT PRIME HUMAN LEUKOCYTE ANTIGEN CLASS I RESTRICTED CD8 T-CELL RESPONSES AGAINST VIRAL NON-VIRION-INTEGRAL DERIVED EPITOPES | CHEN, STACY BROWN | 1672 | §103 | Final Rejection | — | Pending | Sep 27, 2022 |
| 16632301 | A TWO-COMPONENT VECTOR LIBRARY SYSTEM FOR RAPID ASSEMBLY AND DIVERSIFICATION OF FULL-LENGTH T-CELL RECEPTOR OPEN READING FRAMES | MEYERING, SHABANA SHABBEER | 1635 | §103§112Other | Non-Final OA | — | Pending | Jan 17, 2020 |
| 16347691 | AN ENGINEERED MULTI-COMPONENT SYSTEM FOR IDENTIFICATION AND CHARACTERISATION OF T-CELL RECEPTORS, T-CELL ANTIGENS AND THEIR FUNCTIONAL INTERACTION | WILSON, MICHAEL C | 1638 | §112 | Non-Final OA | 57d | Pending | May 06, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial